|
The clinical studies of the miraculous diet
wonder Acomplia (Rimonabant) had proved its
mettle as the new leader of the diet pill market. According
to studies patients who were treated for one year with
Acomplia(Rimonabant) 20 mg per day lost 8.6 kg (almost
20 lbs.) as compared to 2.3 kg (5 lbs.) loss with placebo
(p<0.001).
Nearly 75% (p<0.001 vs. placebo) of patients treated
for one year with ACOMPLIA(TM) 20 mg lost over 5% of
their body weight as compared to 41.8% (p = 0.002 vs.
placebo) of patients on ACOMPLIA(TM) 5 mg and 27.6%
of patients in the placebo group. Moreover, 44.3% (p<0.001
vs. placebo) lost more than 10% of their body weight
when treated for one year with ACOMPLIA(TM) 20 mg vs.
16.3% of patients on ACOMPLIA(TM) 5 mg or 10.3% of patients
on placebo.
In addition to weight loss, RIO-Lipids was designed
to assess a number of associated important cardiovascular
risk factors. All improvements in risk factors were
statistically significant vs. the control group. In
fact, the number of patients diagnosed as having metabolic
syndrome1 at baseline (52.9%) was reduced by half (25.8%)
after treatment with ACOMPLIA(TM) 20 mg (p<0.0001
compared to placebo). Study findings for rimonabant
20 mg include:
- Waist circumference reduction of 9.1 cm (3.5 inches)
in patients treated for a year (completers) with rimonabant
20 mg (p<0.001 vs. placebo).
- Average increase of 23% in HDL-cholesterol in completers
(p<0.001 vs. placebo).
- Average reduction of 15% in triglycerides in completers
(p<0.001 vs. placebo).
- A positive shift in LDL particle size, with a reduction
(p=0.002 vs. placebo) in the proportion of smaller
dense atherogenic LDL particles, which are associated
with cardiovascular risk, and an increase (p<0.001
vs. placebo) in the proportion of larger, less atherogenic
LDL particles.
|
